# Neoadjuvant Befotertinib Combined Bevacizumab or Platinum-based Double Chemotherapy for Resectable Locally-advanced EGFR Mutation-positive Non-Small Cell Lung Cancer

> **NCT06755684** · PHASE2 · RECRUITING · sponsor: **Peng Zhang** · enrollment: 60 (estimated)

## Conditions studied

- EGFR
- Non-Small Cell Lung Cancer
- Locally Advanced Non-Small Cell Lung Cancer
- Pemetrexed
- Carboplatin
- Bevacizumab
- Antineoplastic Agents
- Tyrosine Kinase Inhibitor

## Interventions

- **DRUG:** Befotertinib combined Bevacizumab
- **DRUG:** Befotertinib combined platinum-based double chemotherapy

## Key facts

- **NCT ID:** NCT06755684
- **Lead sponsor:** Peng Zhang
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-07
- **Primary completion:** 2025-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-01-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06755684

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06755684, "Neoadjuvant Befotertinib Combined Bevacizumab or Platinum-based Double Chemotherapy for Resectable Locally-advanced EGFR Mutation-positive Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06755684. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*